A Comprehensive Study of miRNAs in Parkinson’s Disease: Diagnostics
and Therapeutic Approaches

Saima      Owais; Yasir   Hasan   Siddique
doi:10.2174/1871527321666220111152756
Abstract

Parkinson’s disease (PD) is the second most debilitating neurodegenerative movement disorder. It is characterized by the presence of fibrillar alpha-synuclein amassed in the neurons, known as Lewy bodies. Certain cellular and molecular events are involved, leading to the degeneration of dopaminergic neurons. However, the origin and implication of such events are still uncertain. Nevertheless, the role of microRNAs (miRNAs) as important biomarkers and therapeutic molecules is unquestionable. The most challenging task by far in PD treatment has been its late diagnosis followed by therapeutics. miRNAs are an emerging hope to meet the need of early diagnosis, thereby promising an improved movement symptom and prolonged life of the patients. The continuous efforts in discovering the role of miRNAs could be made possible by the utilisation of various animal models of PD. These models help us understand insights into the mechanism of the disease. Moreover, miRNAs have been surfaced as therapeutically important molecules with distinct delivery systems enhancing their success rate. This review aims at providing an outline of different miRNAs implicated in either PD-associated gene regulation or involved in therapeutics.
Keywords: Parkinson’s disease, alpha-synuclein, lewy bodies, micrornas, animal models, fibrillar alpha-synuclein.
« Previous Next »
[1]
Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci  2002; 14(2): 223-36.
 [http://dx.doi.org/10.1176/jnp.14.2.223] [PMID: 11983801]

[2]
Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry  2008; 79(4): 368-76.
 [http://dx.doi.org/10.1136/jnnp.2007.131045] [PMID: 18344392]

[3]
Sherer TB, Chowdhury S, Peabody K, Brooks DW. Overcoming obstacles in Parkinson’s disease. Mov Disord  2012; 27(13): 1606-11.
 [http://dx.doi.org/10.1002/mds.25260] [PMID: 23115047]

[4]
Spratt DE, Martinez-Torres RJ, Noh YJ, et al. A molecular explanation for the recessive nature of parkin-linked Parkinson’s disease. Nat Commun  2013; 4: 1983.
 [http://dx.doi.org/10.1038/ncomms2983] [PMID: 23770917]

[5]
Wang H. MicroRNAs, Parkinson’s disease, and diabetes mellitus. Int J Mol Sci  2021; 22(6): 2953.
 [http://dx.doi.org/10.3390/ijms22062953] [PMID: 33799467]

[6]
Zheng B, Liao Z, Locascio JJ, et al. PGC-1α, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med  2010; 2(52): 52ra73.
 [http://dx.doi.org/10.1126/scitranslmed.3001059] [PMID: 20926834]

[7]
Jodeiri Farshbaf M, Ghaedi K, Megraw TL, et al. Does PGC1α/FNDC5/BDNF elicit the beneficial effects of exercise on neurodegenerative disorders? Neuromolecular Med  2016; 18(1): 1-15.
 [http://dx.doi.org/10.1007/s12017-015-8370-x] [PMID: 26611102]

[8]
Li D, Mastaglia FL, Fletcher S, Wilton SD. Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson’s disease in the precision medicine era. Med Res Rev  2020; 40(6): 2650-81.
 [http://dx.doi.org/10.1002/med.21718] [PMID: 32767426]

[9]
Martinez TN, Greenamyre JT. Toxin models of mitochondrial dysfunction in Parkinson’s disease. Antioxid Redox Signal  2012; 16(9): 920-34.
 [http://dx.doi.org/10.1089/ars.2011.4033] [PMID: 21554057]

[10]
Torok R, Salamon A, Sumegi E, et al. Effect of MPTP on mRNA expression of PGC-1α in mouse brain. Brain Res  2017; 1660: 20-6.
 [http://dx.doi.org/10.1016/j.brainres.2017.01.032] [PMID: 28161458]

[11]
Baghi M, Yadegari E, Rostamian Delavar M, et al. MiR-193b deregulation is associated with Parkinson’s disease. J Cell Mol Med  2021; 25(13): 6348-60.
 [http://dx.doi.org/10.1111/jcmm.16612] [PMID: 34018309]

[12]
Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging  2003; 24(2): 197-211.
 [http://dx.doi.org/10.1016/S0197-4580(02)00065-9] [PMID: 12498954]

[13]
Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res  2004; 318(1): 121-34.
 [http://dx.doi.org/10.1007/s00441-004-0956-9] [PMID: 15338272]

[14]
Hornykiewicz O. Parkinson’s disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv Neurol  1993; 60: 140-7.
 [PMID: 8420131]

[15]
Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm (Vienna)  2004; 111(10-11): 1219-35.
 [http://dx.doi.org/10.1007/s00702-004-0138-7] [PMID: 15480835]

[16]
Saito Y, Ruberu NN, Sawabe M, et al. Lewy body-related alpha-synucleinopathy in aging. J Neuropathol Exp Neurol  2004; 63(7): 742-9.
 [http://dx.doi.org/10.1093/jnen/63.7.742] [PMID: 15290899]

[17]
Miñones-Moyano E, Porta S, Escaramís G, et al. MicroRNA profiling of Parkinson’s disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet  2011; 20(15): 3067-78.
 [http://dx.doi.org/10.1093/hmg/ddr210] [PMID: 21558425]

[18]
Elbaz A, Bower JH, Maraganore DM, et al. Risk tables for parkinsonism and Parkinson’s disease. J Clin Epidemiol  2002; 55(1): 25-31.
 [http://dx.doi.org/10.1016/S0895-4356(01)00425-5] [PMID: 11781119]

[19]
Haaxma CA, Bloem BR, Borm GF, et al. Gender differences in Parkinson’s disease. J Neurol Neurosurg Psychiatry  2007; 78(8): 819-24.
 [http://dx.doi.org/10.1136/jnnp.2006.103788] [PMID: 17098842]

[20]
Cerri S, Mus L, Blandini F. Parkinson’s disease in women and men: What’s the difference? J Parkinsons Dis  2019; 9(3): 501-15.
 [http://dx.doi.org/10.3233/JPD-191683] [PMID: 31282427]

[21]
Tanner CM, Goldman SM. Epidemiology of Parkinson’s disease. Neurol Clin  1996; 14(2): 317-35.
 [http://dx.doi.org/10.1016/S0733-8619(05)70259-0] [PMID: 8827174]

[22]
Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet  2004; 363(9423): 1783-93.
 [http://dx.doi.org/10.1016/S0140-6736(04)16305-8] [PMID: 15172778]

[23]
Shulman JM, De Jager PL, Feany MB. Parkinson’s disease: genetics and pathogenesis. Annu Rev Pathol  2011; 6: 193-222.
 [http://dx.doi.org/10.1146/annurev-pathol-011110-130242] [PMID: 21034221]

[24]
Douglas MR, Lewthwaite AJ, Nicholl DJ. Genetics of Parkinson’s disease and parkinsonism. Expert Rev Neurother  2007; 7(6): 657-66.
 [http://dx.doi.org/10.1586/14737175.7.6.657] [PMID: 17563249]

[25]
Tan EK, Skipper LM. Pathogenic mutations in Parkinson disease. Hum Mutat  2007; 28(7): 641-53.
 [http://dx.doi.org/10.1002/humu.20507] [PMID: 17385668]

[26]
Xiromerisiou G, Dardiotis E, Tsimourtou V, et al. Genetic basis of Parkinson disease. Neurosurg Focus  2010; 28(1): E7.
 [http://dx.doi.org/10.3171/2009.10.FOCUS09220] [PMID: 20043722]

[27]
Gorell JM, Johnson CC, Rybicki BA, et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson’s disease. Neurotoxicology  1999; 20(2-3): 239-47.
 [PMID: 10385887]

[28]
Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology  1998; 50(5): 1346-50.
 [http://dx.doi.org/10.1212/WNL.50.5.1346] [PMID: 9595985]

[29]
Ball N, Teo WP, Chandra S, Chapman J. Parkinson’s disease and the environment. Front Neurol  2019; 10: 218.
 [http://dx.doi.org/10.3389/fneur.2019.00218] [PMID: 30941085]

[30]
Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science  1983; 219(4587): 979-80.
 [http://dx.doi.org/10.1126/science.6823561] [PMID: 6823561]

[31]
Chhillar N, Singh NK, Banerjee BD, et al. Organochlorine pesticide levels and risk of Parkinson’s disease in north Indian population. ISRN Neurol  2013; 2013: 371034.
 [http://dx.doi.org/10.1155/2013/371034] [PMID: 23936670]

[32]
Kanagaraj S, Hema MS, Gupta MN. Environmental risk factors and Parkinson’s disease-A study report.  IJRTE  2018; 7(4): 412-5.

[33]
Kanagaraj N. MicroRNA expressions in the MPTP-induced Parkinson’s disease model with special Reference to miR-124. 2013.

[34]
Shamsuzzama KL, Kumar L, Nazir A. Modulation of alpha-synuclein expression and associated effects by microRNA Let-7 in transgenic C. elegans. Front Mol Neurosci  2017; 10: 328.
 [http://dx.doi.org/10.3389/fnmol.2017.00328] [PMID: 29081733]

[35]
Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet  2007; 8(2): 93-103.
 [http://dx.doi.org/10.1038/nrg1990] [PMID: 17230196]

[36]
Zhang X, Yang R, Hu BL, et al. Reduced circulating levels of miR-433 and miR-133b Are potential biomarkers for Parkinson’s disease. Front Cell Neurosci  2017; 11: 170.
 [http://dx.doi.org/10.3389/fncel.2017.00170] [PMID: 28690499]

[37]
Esquela-Kerscher A. The lin-4 microRNA: The ultimate micromanager. Cell Cycle  2014; 13(7): 1060-1.
 [http://dx.doi.org/10.4161/cc.28384] [PMID: 24584060]

[38]
Jackson RJ, Standart N. How do microRNAs regulate gene expression? Sci STKE  2007; 2007(367): re1.
 [http://dx.doi.org/10.1126/stke.3672007re1] [PMID: 17200520]

[39]
Krichevsky AM, King KS, Donahue CP, Khrapko K, Kosik KS. A microRNA array reveals extensive regulation of microRNAs during brain development. RNA  2003; 9(10): 1274-81.
 [http://dx.doi.org/10.1261/rna.5980303] [PMID: 13130141]

[40]
Krichevsky AM, Sonntag KC, Isacson O, Kosik KS. Specific microRNAs modulate embryonic stem cell-derived neurogenesis. Stem Cells  2006; 24(4): 857-64.
 [http://dx.doi.org/10.1634/stemcells.2005-0441] [PMID: 16357340]

[41]
Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol  2004; 5(3): R13.
 [http://dx.doi.org/10.1186/gb-2004-5-3-r13] [PMID: 15003116]

[42]
Schratt GM, Tuebing F, Nigh EA, et al. A brain-specific microRNA regulates dendritic spine development. Nature  2006; 439(7074): 283-9.
 [http://dx.doi.org/10.1038/nature04367] [PMID: 16421561]

[43]
Asikainen S, Rudgalvyte M, Heikkinen L, et al. Global microRNA expression profiling of Caenorhabditis elegans Parkinson’s disease models. J Mol Neurosci  2010; 41(1): 210-8.
 [http://dx.doi.org/10.1007/s12031-009-9325-1] [PMID: 20091141]

[44]
Sonntag KC. MicroRNAs and deregulated gene expression networks in neurodegeneration. Brain Res  2010; 1338: 48-57.
 [http://dx.doi.org/10.1016/j.brainres.2010.03.106] [PMID: 20380815]

[45]
Kumar M, Nath S, Prasad HK, Sharma GD, Li Y. MicroRNAs: a new ray of hope for diabetes mellitus. Protein Cell  2012; 3(10): 726-38.
 [http://dx.doi.org/10.1007/s13238-012-2055-0] [PMID: 23055040]

[46]
Dimmeler S, Nicotera P. MicroRNAs in age-related diseases. EMBO Mol Med  2013; 5(2): 180-90.
 [http://dx.doi.org/10.1002/emmm.201201986] [PMID: 23339066]

[47]
Kocerha J, Xu Y, Prucha MS, Zhao D, Chan AW. microRNA-128a dysregulation in transgenic Huntington’s disease monkeys. Mol Brain  2014; 7: 46.
 [http://dx.doi.org/10.1186/1756-6606-7-46] [PMID: 24929669]

[48]
Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by the Microprocessor complex. Nature  2004; 432(7014): 231-5.
 [http://dx.doi.org/10.1038/nature03049] [PMID: 15531879]

[49]
Alarcón CR, Lee H, Goodarzi H, Halberg N, Tavazoie SF. N6-methyladenosine marks primary microRNAs for processing. Nature  2015; 519(7544): 482-5.
 [http://dx.doi.org/10.1038/nature14281] [PMID: 25799998]

[50]
Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev  2004; 18(24): 3016-27.
 [http://dx.doi.org/10.1101/gad.1262504] [PMID: 15574589]

[51]
O’Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne)  2018; 9: 402.
 [http://dx.doi.org/10.3389/fendo.2018.00402] [PMID: 30123182]

[52]
Lund E, Güttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science  2004; 303(5654): 95-8.
 [http://dx.doi.org/10.1126/science.1090599] [PMID: 14631048]

[53]
Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev  2003; 17(24): 3011-6.
 [http://dx.doi.org/10.1101/gad.1158803] [PMID: 14681208]

[54]
Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA  2004; 10(2): 185-91.
 [http://dx.doi.org/10.1261/rna.5167604] [PMID: 14730017]

[55]
Ghosh S. Micro RNA-biogenesis, mechanism of action and applications-A review. Res J Biotechnol  2011; 1(1): 11-36.

[56]
Okada C, Yamashita E, Lee SJ, et al. A high-resolution structure of the pre-microRNA nuclear export machinery. Science  2009; 326(5957): 1275-9.
 [http://dx.doi.org/10.1126/science.1178705] [PMID: 19965479]

[57]
Zhang H, Kolb FA, Jaskiewicz L, Westhof E, Filipowicz W. Single processing center models for human Dicer and bacterial RNase III. Cell  2004; 118(1): 57-68.
 [http://dx.doi.org/10.1016/j.cell.2004.06.017] [PMID: 15242644]

[58]
Yoda M, Kawamata T, Paroo Z, et al. ATP-dependent human RISC assembly pathways. Nat Struct Mol Biol  2010; 17(1): 17-23.
 [http://dx.doi.org/10.1038/nsmb.1733] [PMID: 19966796]

[59]
Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell  2003; 115(2): 209-16.
 [http://dx.doi.org/10.1016/S0092-8674(03)00801-8] [PMID: 14567918]

[60]
Vasudevan S, Steitz JA. AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2. Cell  2007; 128(6): 1105-18.
 [http://dx.doi.org/10.1016/j.cell.2007.01.038] [PMID: 17382880]

[61]
Bai X, Tang Y, Yu M, et al. Downregulation of blood serum microRNA 29 family in patients with Parkinson’s disease. Sci Rep  2017; 7(1): 5411.
 [http://dx.doi.org/10.1038/s41598-017-03887-3] [PMID: 28710399]

[62]
Chen Y, Gao C, Sun Q, et al. MicroRNA-4639 is a regulator of DJ-1 expression and a potential early diagnostic marker for Parkinson’s disease. Front Aging Neurosci  2017; 9: 232.
 [http://dx.doi.org/10.3389/fnagi.2017.00232] [PMID: 28785216]

[63]
Dong H, Wang C, Lu S, et al. A panel of four decreased serum microRNAs as a novel biomarker for early Parkinson’s disease. Biomarkers  2016; 21(2): 129-37.
 [http://dx.doi.org/10.3109/1354750X.2015.1118544] [PMID: 26631297]

[64]
Chen Y, Lian YJ, Ma YQ, Wu CJ, Zheng YK, Xie NC. LncRNA SNHG1 promotes α-synuclein aggregation and toxicity by targeting miR-15b-5p to activate SIAH1 in human neuroblastoma SH-SY5Y cells. Neurotoxicology  2018; 68: 212-21.
 [http://dx.doi.org/10.1016/j.neuro.2017.12.001] [PMID: 29217406]

[65]
Schwienbacher C, Foco L, Picard A, et al. Plasma and white blood cells show different miRNA expression profiles in Parkinson’s disease. J Mol Neurosci  2017; 62(2): 244-54.
 [http://dx.doi.org/10.1007/s12031-017-0926-9] [PMID: 28540642]

[66]
Burgos K, Malenica I, Metpally R, et al. Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer’s and Parkinson’s diseases correlate with disease status and features of pathology. PLoS One  2014; 9(5): e94839.
 [http://dx.doi.org/10.1371/journal.pone.0094839] [PMID: 24797360]

[67]
Martins M, Rosa A, Guedes LC, et al. Convergence of miRNA expression profiling, α-synuclein interacton and GWAS in Parkinson’s disease. PLoS One  2011; 6(10): e25443.
 [http://dx.doi.org/10.1371/journal.pone.0025443] [PMID: 22003392]

[68]
Gui Y, Liu H, Zhang L, Lv W, Hu X. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget  2015; 6(35): 37043-53.
 [http://dx.doi.org/10.18632/oncotarget.6158] [PMID: 26497684]

[69]
Briggs CE, Wang Y, Kong B, Woo TU, Iyer LK, Sonntag KC. Midbrain dopamine neurons in Parkinson’s disease exhibit a dysregulated miRNA and target-gene network. Brain Res  2015; 1618: 111-21.
 [http://dx.doi.org/10.1016/j.brainres.2015.05.021] [PMID: 26047984]

[70]
Tatura R, Kraus T, Giese A, et al. Parkinson’s disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus. Parkinsonism Relat Disord  2016; 33: 115-21.
 [http://dx.doi.org/10.1016/j.parkreldis.2016.09.028] [PMID: 27717584]

[71]
Chatterjee P, Roy D. Comparative analysis of RNA-Seq data from brain and blood samples of Parkinson’s disease. Biochem Biophys Res Commun  2017; 484(3): 557-64.
 [http://dx.doi.org/10.1016/j.bbrc.2017.01.121] [PMID: 28131841]

[72]
Wang G, van der Walt JM, Mayhew G, et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet  2008; 82(2): 283-9.
 [http://dx.doi.org/10.1016/j.ajhg.2007.09.021] [PMID: 18252210]

[73]
Filatova EV, Alieva AKh, Shadrina MI, Slominsky PA. MicroRNAs: possible role in pathogenesis of Parkinson’s disease. Biochemistry (Mosc)  2012; 77(8): 813-9.
 [http://dx.doi.org/10.1134/S0006297912080020] [PMID: 22860903]

[74]
da Silva FC, Iop RD, Vietta GG, et al. microRNAs involved in Parkinson’s disease: A systematic review. Mol Med Rep  2016; 14(5): 4015-22.
 [http://dx.doi.org/10.3892/mmr.2016.5759] [PMID: 27666518]

[75]
Shen YF, Zhu ZY, Qian SX, Xu CY, Wang YP. miR-30b protects nigrostriatal dopaminergic neurons from MPP(+)-induced neurotoxicity via SNCA. Brain Behav  2020; 10(4): e01567.
 [http://dx.doi.org/10.1002/brb3.1567] [PMID: 32154657]

[76]
Wang Y, Zhang X, Li H, Yu J, Ren X. The role of miRNA-29 family in cancer. Eur J Cell Biol  2013; 92(3): 123-8.
 [http://dx.doi.org/10.1016/j.ejcb.2012.11.004] [PMID: 23357522]

[77]
Yan B, Guo Q, Fu FJ, et al. The role of miR-29b in cancer: regulation, function, and signaling. OncoTargets Ther  2015; 8: 539-48.
 [PMID: 25767398]

[78]
Kole AJ, Swahari V, Hammond SM, Deshmukh M. miR-29b is activated during neuronal maturation and targets BH3-only genes to restrict apoptosis. Genes Dev  2011; 25(2): 125-30.
 [http://dx.doi.org/10.1101/gad.1975411] [PMID: 21245165]

[79]
Ugalde AP, Ramsay AJ, de la Rosa J, et al. Aging and chronic DNA damage response activate a regulatory pathway involving miR-29 and p53. EMBO J  2011; 30(11): 2219-32.
 [http://dx.doi.org/10.1038/emboj.2011.124] [PMID: 21522133]

[80]
Botta-Orfila T, Morató X, Compta Y, et al. Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson’s disease. J Neurosci Res  2014; 92(8): 1071-7.
 [http://dx.doi.org/10.1002/jnr.23377] [PMID: 24648008]

[81]
Ma W, Li Y, Wang C, Xu F, Wang M, Liu Y. Serum miR-221 serves as a biomarker for Parkinson’s disease. Cell Biochem Funct  2016; 34(7): 511-5.
 [http://dx.doi.org/10.1002/cbf.3224] [PMID: 27748571]

[82]
Margis R, Margis R, Rieder CR. Identification of blood microRNAs associated to Parkinsonĭs disease. J Biotechnol  2011; 152(3): 96-101.
 [http://dx.doi.org/10.1016/j.jbiotec.2011.01.023] [PMID: 21295623]

[83]
Roshan R, Shridhar S, Sarangdhar MA, et al. Brain-specific knockdown of miR-29 results in neuronal cell death and ataxia in mice. RNA  2014; 20(8): 1287-97.
 [http://dx.doi.org/10.1261/rna.044008.113] [PMID: 24958907]

[84]
Cao L, Zhang Y, Zhang S, et al. MicroRNA-29b alleviates oxygen and glucose deprivation/reperfusion-induced injury via inhibition of the p53-dependent apoptosis pathway in N2a neuroblastoma cells. Exp Ther Med  2018; 15(1): 67-74.
 [PMID: 29399057]

[85]
Lyu G, Guan Y, Zhang C, et al. TGF-β signaling alters H4K20me3 status via miR-29 and contributes to cellular senescence and cardiac aging. Nat Commun  2018; 9(1): 2560.
 [http://dx.doi.org/10.1038/s41467-018-04994-z] [PMID: 29967491]

[86]
Morita S, Horii T, Kimura M, Ochiya T, Tajima S, Hatada I. miR-29 represses the activities of DNA methyltransferases and DNA demethylases. Int J Mol Sci  2013; 14(7): 14647-58.
 [http://dx.doi.org/10.3390/ijms140714647] [PMID: 23857059]

[87]
Goh SY, Chao YX, Dheen ST, Tan EK, Tay SS. Role of microRNAs in Parkinson’s disease. Int J Mol Sci  2019; 20(22): 5649.
 [http://dx.doi.org/10.3390/ijms20225649] [PMID: 31718095]

[88]
Li L, Liu H, Song H, et al. Let-7d microRNA attenuates 6-OHDA-induced injury by targeting caspase-3 in MN9D cells. J Mol Neurosci  2017; 63(3-4): 403-11.
 [http://dx.doi.org/10.1007/s12031-017-0994-x] [PMID: 29082467]

[89]
Wang S, Tang Y, Cui H, et al. Let-7/miR-98 regulate Fas and Fas- mediated apoptosis. Genes Immun  2011; 12(2): 149-54.
 [http://dx.doi.org/10.1038/gene.2010.53] [PMID: 21228813]

[90]
Jiang S, Yan W, Wang SE, Baltimore D. Let-7 suppresses B cell activation through restricting the availability of necessary nutrients. Cell Metab  2018; 27(2): 393-403.e4.
 [http://dx.doi.org/10.1016/j.cmet.2017.12.007] [PMID: 29337138]

[91]
Schulte LN, Eulalio A, Mollenkopf HJ, Reinhardt R, Vogel J. Analysis of the host microRNA response to Salmonella uncovers the control of major cytokines by the let-7 family. EMBO J  2011; 30(10): 1977-89.
 [http://dx.doi.org/10.1038/emboj.2011.94] [PMID: 21468030]

[92]
Sinigaglia K, Wiatrek D, Khan A, et al. ADAR RNA editing in innate immune response phasing, in circadian clocks and in sleep. Biochim Biophys Acta Gene Regul Mech  2019; 1862(3): 356-69.
 [http://dx.doi.org/10.1016/j.bbagrm.2018.10.011] [PMID: 30391332]

[93]
Benhamed M, Herbig U, Ye T, Dejean A, Bischof O. Senescence is an endogenous trigger for microRNA-directed transcriptional gene silencing in human cells. Nat Cell Biol  2012; 14(3): 266-75.
 [http://dx.doi.org/10.1038/ncb2443] [PMID: 22366686]

[94]
Rom S, Dykstra H, Zuluaga-Ramirez V, Reichenbach NL, Persidsky Y. miR-98 and let-7g* protect the blood-brain barrier under neuroinflammatory conditions. J Cereb Blood Flow Metab  2015; 35(12): 1957-65.
 [http://dx.doi.org/10.1038/jcbfm.2015.154] [PMID: 26126865]

[95]
Cardo LF, Coto E, Ribacoba R, et al. MiRNA profile in the substantia nigra of Parkinson’s disease and healthy subjects. J Mol Neurosci  2014; 54(4): 830-6.
 [http://dx.doi.org/10.1007/s12031-014-0428-y] [PMID: 25284245]

[96]
Nair VD, Ge Y. Alterations of miRNAs reveal a dysregulated molecular regulatory network in Parkinson’s disease striatum. Neurosci Lett  2016; 629: 99-104.
 [http://dx.doi.org/10.1016/j.neulet.2016.06.061] [PMID: 27369327]

[97]
Lin X, Wang R, Li R, Tao T, Zhang D, Qi Y. Diagnostic performance of miR-485-3p in patients with parkinson’s disease and its relationship with neuroinflammation.  Neuromolecular Med 2021. [Online ahead of print]
 [http://dx.doi.org/10.1007/s12017-021-08676-w]

[98]
Wang J, Li HY, Wang HS, Su ZB. MicroRNA-485 modulates the TGF-β/ Smads signaling pathway in chronic asthmatic mice by targeting Smurf2. Cell Physiol Biochem  2018; 51(2): 692-710.
 [http://dx.doi.org/10.1159/000495327] [PMID: 30463065]

[99]
Chen Z, Zhang Z, Zhang D, Li H, Sun Z. Hydrogen sulfide protects against TNF-α induced neuronal cell apoptosis through miR-485-5p/TRADD signaling. Biochem Biophys Res Commun  2016; 478(3): 1304-9.
 [http://dx.doi.org/10.1016/j.bbrc.2016.08.116] [PMID: 27562714]

[100]
Horst CH, Schlemmer F, de Aguiar Montenegro N, et al. Signature of aberrantly expressed microRNAs in the striatum of rotenone-induced Parkinsonian rats. Neurochem Res  2018; 43(11): 2132-40.
 [http://dx.doi.org/10.1007/s11064-018-2638-0] [PMID: 30267378]

[101]
Dorval V, Mandemakers W, Jolivette F, et al. Gene and MicroRNA transcriptome analysis of Parkinson’s related LRRK2 mouse models. PLoS One  2014; 9(1): e85510.
 [http://dx.doi.org/10.1371/journal.pone.0085510] [PMID: 24427314]

[102]
Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson’s disease. Neuron  2015; 85(2): 257-73.
 [http://dx.doi.org/10.1016/j.neuron.2014.12.007] [PMID: 25611507]

[103]
He Y, Liu H, Jiang L, Rui B, Mei J, Xiao H. miR-26 induces apoptosis and inhibits autophagy in non-small cell lung cancer cells by suppressing TGF-β1-JNK signaling pathway. Front Pharmacol  2019; 9: 1509.
 [http://dx.doi.org/10.3389/fphar.2018.01509] [PMID: 30687089]

[104]
Alim MA, Hossain MS, Arima K, et al. Tubulin seeds alpha-synuclein fibril formation. J Biol Chem  2002; 277(3): 2112-7.
 [http://dx.doi.org/10.1074/jbc.M102981200] [PMID: 11698390]

[105]
Totterdell S, Meredith GE. Localization of alpha-synuclein to identified fibers and synapses in the normal mouse brain. Neuroscience  2005; 135(3): 907-13.
 [http://dx.doi.org/10.1016/j.neuroscience.2005.06.047] [PMID: 16112475]

[106]
Maroteaux L, Scheller RH. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res Mol Brain Res  1991; 11(3-4): 335-43.
 [http://dx.doi.org/10.1016/0169-328X(91)90043-W] [PMID: 1661825]

[107]
Uéda K, Fukushima H, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA  1993; 90(23): 11282-6.
 [http://dx.doi.org/10.1073/pnas.90.23.11282] [PMID: 8248242]

[108]
George JM. The synucleins. Genome Biol  2002; 3(1): S3002.
 [PMID: 11806835]

[109]
Chandra S, Gallardo G, Fernández-Chacón R, Schlüter OM, Südhof TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell  2005; 123(3): 383-96.
 [http://dx.doi.org/10.1016/j.cell.2005.09.028] [PMID: 16269331]

[110]
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature  1997; 388(6645): 839-40.
 [http://dx.doi.org/10.1038/42166] [PMID: 9278044]

[111]
Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA  2000; 97(2): 571-6.
 [http://dx.doi.org/10.1073/pnas.97.2.571] [PMID: 10639120]

[112]
Charvin D, Medori R, Hauser RA, Rascol O. Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov  2018; 17(11): 804-22.
 [http://dx.doi.org/10.1038/nrd.2018.136] [PMID: 30262889]

[113]
Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem  2000; 275(24): 18344-9.
 [http://dx.doi.org/10.1074/jbc.M000206200] [PMID: 10747881]

[114]
Zhao L, Wang Z. MicroRNAs: Game Changers in the Regulation of α-Synuclein in Parkinson’s Disease. Parkinsons Dis  2019; 2019: 1743183.
 [http://dx.doi.org/10.1155/2019/1743183] [PMID: 31191899]

[115]
Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci  2013; 14(1): 38-48.
 [http://dx.doi.org/10.1038/nrn3406] [PMID: 23254192]

[116]
Oueslati A, Paleologou KE, Schneider BL, Aebischer P, Lashuel HA. Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson’s disease. J Neurosci  2012; 32(5): 1536-44.
 [http://dx.doi.org/10.1523/JNEUROSCI.3784-11.2012] [PMID: 22302797]

[117]
Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem  2003; 278(27): 25009-13.
 [http://dx.doi.org/10.1074/jbc.M300227200] [PMID: 12719433]

[118]
Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science  2004; 305(5688): 1292-5.
 [http://dx.doi.org/10.1126/science.1101738] [PMID: 15333840]

[119]
Spencer B, Potkar R, Trejo M, et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson’s and Lewy body diseases. J Neurosci  2009; 29(43): 13578-88.
 [http://dx.doi.org/10.1523/JNEUROSCI.4390-09.2009] [PMID: 19864570]

[120]
Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 reduces alpha-synuclein aggregation and toxicity. J Biol Chem  2004; 279(24): 25497-502.
 [http://dx.doi.org/10.1074/jbc.M400255200] [PMID: 15044495]

[121]
Crews L, Spencer B, Desplats P, et al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One  2010; 5(2): e9313.
 [http://dx.doi.org/10.1371/journal.pone.0009313] [PMID: 20174468]

[122]
Lee HJ, Khoshaghideh F, Patel S, Lee SJ. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci  2004; 24(8): 1888-96.
 [http://dx.doi.org/10.1523/JNEUROSCI.3809-03.2004] [PMID: 14985429]

[123]
Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem  2008; 283(35): 23542-56.
 [http://dx.doi.org/10.1074/jbc.M801992200] [PMID: 18566453]

[124]
Mak SK, McCormack AL, Manning-Bog AB, Cuervo AM, Di Monte DA. Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem  2010; 285(18): 13621-9.
 [http://dx.doi.org/10.1074/jbc.M109.074617] [PMID: 20200163]

[125]
Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L. Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One  2009; 4(5): e5515.
 [http://dx.doi.org/10.1371/journal.pone.0005515] [PMID: 19436756]

[126]
Robert G, Jacquel A, Auberger P. Chaperone-mediated autophagy and its emerging role in hematological malignancies. Cells  2019; 8(10): 1260.
 [http://dx.doi.org/10.3390/cells8101260] [PMID: 31623164]

[127]
Xu CY, Kang WY, Chen YM, et al. DJ-1 inhibits α-synuclein aggregation by regulating chaperone-mediated autophagy. Front Aging Neurosci  2017; 9: 308.
 [http://dx.doi.org/10.3389/fnagi.2017.00308] [PMID: 29021755]

[128]
Crotzer VL, Blum JS. Autophagy and intracellular surveillance: Modulating MHC class II antigen presentation with stress. Proc Natl Acad Sci USA  2005; 102(22): 7779-80.
 [http://dx.doi.org/10.1073/pnas.0503088102] [PMID: 15911750]

[129]
Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson’s disease. Brain  2008; 131(Pt 8): 1969-78.
 [http://dx.doi.org/10.1093/brain/awm318] [PMID: 18187492]

[130]
Kuma A, Hatano M, Matsui M, et al. The role of autophagy during the early neonatal starvation period. Nature  2004; 432(7020): 1032-6.
 [http://dx.doi.org/10.1038/nature03029] [PMID: 15525940]

[131]
Hara T, Nakamura K, Matsui M, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature  2006; 441(7095): 885-9.
 [http://dx.doi.org/10.1038/nature04724] [PMID: 16625204]

[132]
Komatsu M, Waguri S, Chiba T, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature  2006; 441(7095): 880-4.
 [http://dx.doi.org/10.1038/nature04723] [PMID: 16625205]

[133]
Massey AC, Kaushik S, Sovak G, Kiffin R, Cuervo AM. Consequences of the selective blockage of chaperone-mediated autophagy. Proc Natl Acad Sci USA  2006; 103(15): 5805-10.
 [http://dx.doi.org/10.1073/pnas.0507436103] [PMID: 16585521]

[134]
Bardien S, Lesage S, Brice A, Carr J. Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson’s disease. Parkinsonism Relat Disord  2011; 17(7): 501-8.
 [http://dx.doi.org/10.1016/j.parkreldis.2010.11.008] [PMID: 21641266]

[135]
Mortiboys H, Johansen KK, Aasly JO, Bandmann O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology  2010; 75(22): 2017-20.
 [http://dx.doi.org/10.1212/WNL.0b013e3181ff9685] [PMID: 21115957]

[136]
Delcambre S, Ghelfi J, Ouzren N, et al. Mitochondrial mechanisms of LRRK2 G2019S penetrance. Front Neurol  2020; 11: 881.
 [http://dx.doi.org/10.3389/fneur.2020.00881] [PMID: 32982917]

[137]
Sanders LH, Laganière J, Cooper O, et al. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson’s disease patients: reversal by gene correction. Neurobiol Dis  2014; 62: 381-6.
 [http://dx.doi.org/10.1016/j.nbd.2013.10.013] [PMID: 24148854]

[138]
Schapansky J, Khasnavis S, DeAndrade MP, et al. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons. Neurobiol Dis  2018; 111: 26-35.
 [http://dx.doi.org/10.1016/j.nbd.2017.12.005] [PMID: 29246723]

[139]
Korecka JA, Thomas R, Christensen DP, et al. Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson’s disease patient fibroblasts. Hum Mol Genet  2019; 28(19): 3232-43.
 [http://dx.doi.org/10.1093/hmg/ddz126] [PMID: 31261377]

[140]
Singh F, Ganley IG. Parkinson’s disease and mitophagy: an emerging role for LRRK2. Biochem Soc Trans  2021; 49(2): 551-62.
 [http://dx.doi.org/10.1042/BST20190236] [PMID: 33769432]

[141]
Rideout HJ, Stefanis L. The neurobiology of LRRK2 and its role in the pathogenesis of Parkinson’s disease. Neurochem Res  2014; 39(3): 576-92.
 [http://dx.doi.org/10.1007/s11064-013-1073-5] [PMID: 23729298]

[142]
Li JQ, Tan L, Yu JT. The role of the LRRK2 gene in Parkinsonism. Mol Neurodegener  2014; 9: 47.
 [http://dx.doi.org/10.1186/1750-1326-9-47] [PMID: 25391693]

[143]
Shimura H, Hattori N, Kubo Si, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet  2000; 25(3): 302-5.
 [http://dx.doi.org/10.1038/77060] [PMID: 10888878]

[144]
Tanaka K, Suzuki T, Chiba T, Shimura H, Hattori N, Mizuno Y. Parkin is linked to the ubiquitin pathway. J Mol Med (Berl)  2001; 79(9): 482-94.
 [http://dx.doi.org/10.1007/s001090100242] [PMID: 11692161]

[145]
Periquet M, Latouche M, Lohmann E, et al. Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain  2003; 126(Pt 6): 1271-8.
 [http://dx.doi.org/10.1093/brain/awg136] [PMID: 12764050]

[146]
Sriram SR, Li X, Ko HS, et al. Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum Mol Genet  2005; 14(17): 2571-86.
 [http://dx.doi.org/10.1093/hmg/ddi292] [PMID: 16049031]

[147]
Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature  1998; 392(6676): 605-8.
 [http://dx.doi.org/10.1038/33416] [PMID: 9560156]

[148]
Lücking CB, Dürr A, Bonifati V, et al. Association between early-onset Parkinson’s disease and mutations in the parkin gene. N Engl J Med  2000; 342(21): 1560-7.
 [http://dx.doi.org/10.1056/NEJM200005253422103] [PMID: 10824074]

[149]
Kamienieva I, Duszyński J, Szczepanowska J. Multitasking guardian of mitochondrial quality: Parkin function and Parkinson’s disease. Transl Neurodegener  2021; 10(1): 5.
 [http://dx.doi.org/10.1186/s40035-020-00229-8] [PMID: 33468256]

[150]
Petrucelli L, O’Farrell C, Lockhart PJ, et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron  2002; 36(6): 1007-19.
 [http://dx.doi.org/10.1016/S0896-6273(02)01125-X] [PMID: 12495618]

[151]
Tsai YC, Fishman PS, Thakor NV, Oyler GA. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem  2003; 278(24): 22044-55.
 [http://dx.doi.org/10.1074/jbc.M212235200] [PMID: 12676955]

[152]
Mata IF, Lockhart PJ, Farrer MJ. Parkin genetics: one model for Parkinson’s disease. Hum Mol Genet  2004; 13(Spec No 1): R127-33.
 [http://dx.doi.org/10.1093/hmg/ddh089] [PMID: 14976155]

[153]
Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ, Wood NW. The role of pathogenic DJ-1 mutations in Parkinson’s disease. Ann Neurol  2003; 54(3): 283-6.
 [http://dx.doi.org/10.1002/ana.10675] [PMID: 12953260]

[154]
Kilarski LL, Pearson JP, Newsway V, et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson’s disease. Mov Disord  2012; 27(12): 1522-9.
 [http://dx.doi.org/10.1002/mds.25132] [PMID: 22956510]

[155]
Billia F, Hauck L, Grothe D, et al. Parkinson-susceptibility gene DJ-1/PARK7 protects the murine heart from oxidative damage in vivo. Proc Natl Acad Sci USA  2013; 110(15): 6085-90.
 [http://dx.doi.org/10.1073/pnas.1303444110] [PMID: 23530187]

[156]
Hayashi T, Ishimori C, Takahashi-Niki K, et al. DJ-1 binds to mitochondrial complex I and maintains its activity. Biochem Biophys Res Commun  2009; 390(3): 667-72.
 [http://dx.doi.org/10.1016/j.bbrc.2009.10.025] [PMID: 19822128]

[157]
Zhang L, Shimoji M, Thomas B, et al. Mitochondrial localization of the Parkinson’s disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet  2005; 14(14): 2063-73.
 [http://dx.doi.org/10.1093/hmg/ddi211] [PMID: 15944198]

[158]
Heo JY, Park JH, Kim SJ, et al. DJ-1 null dopaminergic neuronal cells exhibit defects in mitochondrial function and structure: involvement of mitochondrial complex I assembly. PLoS One  2012; 7(3): e32629.
 [http://dx.doi.org/10.1371/journal.pone.0032629] [PMID: 22403686]

[159]
Aryal B, Lee Y. Disease model organism for Parkinson disease: Drosophila melanogaster. BMB Rep  2019; 52(4): 250-8.
 [http://dx.doi.org/10.5483/BMBRep.2019.52.4.204] [PMID: 30545438]

[160]
Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet  2009; 373(9680): 2055-66.
 [http://dx.doi.org/10.1016/S0140-6736(09)60492-X] [PMID: 19524782]

[161]
Fleming SM, Chesselet MF. Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism. Behav Pharmacol  2006; 17(5-6): 383-91.
 [http://dx.doi.org/10.1097/00008877-200609000-00004] [PMID: 16940759]

[162]
Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res  1978; 38(11 Pt 1): 3751-7.

[163]
Påhlman S, Hoehner JC, Nånberg E, et al. Differentiation and survival influences of growth factors in human neuroblastoma. Eur J Cancer  1995; 31A(4): 453-8.
 [http://dx.doi.org/10.1016/0959-8049(95)00033-F] [PMID: 7576944]

[164]
Encinas M, Iglesias M, Liu Y, et al. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem  2000; 75(3): 991-1003.
 [http://dx.doi.org/10.1046/j.1471-4159.2000.0750991.x] [PMID: 10936180]

[165]
Esper RM, Pankonin MS, Loeb JA. Neuregulins: versatile growth and differentiation factors in nervous system development and human disease. Brain Res Brain Res Rev  2006; 51(2): 161-75.
 [http://dx.doi.org/10.1016/j.brainresrev.2005.11.006] [PMID: 16412517]

[166]
Gerecke KM, Wyss JM, Carroll SL. Neuregulin-1beta induces neurite extension and arborization in cultured hippocampal neurons. Mol Cell Neurosci  2004; 27(4): 379-93.
 [http://dx.doi.org/10.1016/j.mcn.2004.08.001] [PMID: 15555917]

[167]
Moore TB, Sidell N, Chow VJ, et al. Differentiating effects of 1,25-dihydroxycholecalciferol (D3) on LA-N-5 human neuroblastoma cells and its synergy with retinoic acid. J Pediatr Hematol Oncol  1995; 17(4): 311-7.
 [http://dx.doi.org/10.1097/00043426-199511000-00006] [PMID: 7583386]

[168]
Sarkanen JR, Nykky J, Siikanen J, Selinummi J, Ylikomi T, Jalonen TO. Cholesterol supports the retinoic acid-induced synaptic vesicle formation in differentiating human SH-SY5Y neuroblastoma cells. J Neurochem  2007; 102(6): 1941-52.
 [http://dx.doi.org/10.1111/j.1471-4159.2007.04676.x] [PMID: 17540009]

[169]
Reddy CD, Patti R, Guttapalli A, et al. Anticancer effects of the novel 1alpha, 25-dihydroxyvitamin D3 hybrid analog QW1624F2-2 in human neuroblastoma. J Cell Biochem  2006; 97(1): 198-206.
 [http://dx.doi.org/10.1002/jcb.20629] [PMID: 16200638]

[170]
Agholme L, Lindström T, Kågedal K, Marcusson J, Hallbeck M. An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J Alzheimers Dis  2010; 20(4): 1069-82.
 [http://dx.doi.org/10.3233/JAD-2010-091363] [PMID: 20413890]

[171]
Kume T, Kawato Y, Osakada F, et al. Dibutyryl cyclic AMP induces differentiation of human neuroblastoma SH-SY5Y cells into a noradrenergic phenotype. Neurosci Lett  2008; 443(3): 199-203.
 [http://dx.doi.org/10.1016/j.neulet.2008.07.079] [PMID: 18691633]

[172]
Guarnieri S, Pilla R, Morabito C, et al. Extracellular guanosine and GTP promote expression of differentiation markers and induce S-phase cell-cycle arrest in human SH-SY5Y neuroblastoma cells. Int J Dev Neurosci  2009; 27(2): 135-47.
 [http://dx.doi.org/10.1016/j.ijdevneu.2008.11.007] [PMID: 19111604]

[173]
Mollereau C, Zajac JM, Roumy M. Staurosporine differentiation of NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells induces selectivity of NPFF activity towards opioid receptors. Peptides  2007; 28(5): 1125-8.
 [http://dx.doi.org/10.1016/j.peptides.2007.03.001] [PMID: 17418451]

[174]
Xie HR, Hu LS, Li GY. SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson’s disease. Chin Med J (Engl)  2010; 123(8): 1086-92.
 [PMID: 20497720]

[175]
Xicoy H, Wieringa B, Martens GJ. The SH-SY5Y cell line in Parkinson’s disease research: a systematic review. Mol Neurodegener  2017; 12(1): 10.
 [http://dx.doi.org/10.1186/s13024-017-0149-0] [PMID: 28118852]

[176]
Ciccarone V, Spengler BA, Meyers MB, Biedler JL, Ross RA. Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res  1989; 49(1): 219-25.
 [PMID: 2535691]

[177]
Junn E, Lee KW, Jeong BS, Chan TW, Im JY, Mouradian MM. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci USA  2009; 106(31): 13052-7.
 [http://dx.doi.org/10.1073/pnas.0906277106] [PMID: 19628698]

[178]
Franco-Zorrilla JM, Valli A, Todesco M, et al. Target mimicry provides a new mechanism for regulation of microRNA activity. Nat Genet  2007; 39(8): 1033-7.
 [http://dx.doi.org/10.1038/ng2079] [PMID: 17643101]

[179]
Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature  2010; 465(7301): 1033-8.
 [http://dx.doi.org/10.1038/nature09144] [PMID: 20577206]

[180]
Cesana M, Cacchiarelli D, Legnini I, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell  2011; 147(2): 358-69.
 [http://dx.doi.org/10.1016/j.cell.2011.09.028] [PMID: 22000014]

[181]
Karreth FA, Tay Y, Perna D, et al. In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell  2011; 147(2): 382-95.
 [http://dx.doi.org/10.1016/j.cell.2011.09.032] [PMID: 22000016]

[182]
Tay Y, Kats L, Salmena L, et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell  2011; 147(2): 344-57.
 [http://dx.doi.org/10.1016/j.cell.2011.09.029] [PMID: 22000013]

[183]
Sumazin P, Yang X, Chiu HS, et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell  2011; 147(2): 370-81.
 [http://dx.doi.org/10.1016/j.cell.2011.09.041] [PMID: 22000015]

[184]
Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature  2013; 495(7441): 384-8.
 [http://dx.doi.org/10.1038/nature11993] [PMID: 23446346]

[185]
Wang ZH, Zhang JL, Duan YL, Zhang QS, Li GF, Zheng DL. MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting α-synuclein expression in MPTP-induced Parkinson’s disease mouse. Biomed Pharmacother  2015; 74: 252-6.
 [http://dx.doi.org/10.1016/j.biopha.2015.08.025] [PMID: 26349993]

[186]
Rott R, Szargel R, Haskin J, et al. Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J Biol Chem  2008; 283(6): 3316-28.
 [http://dx.doi.org/10.1074/jbc.M704809200] [PMID: 18070888]

[187]
Jiang J, Xiong R, Lu J, Wang X, Gu X. MicroRNA-203a-3p regulates the apoptosis of MPP+ Induced SH-SY5Y cells by targeting A-synuclein. J Biomater Tissue Eng  2020; 10(6): 838-44.
 [http://dx.doi.org/10.1166/jbt.2020.2320]

[188]
Alvarez-Erviti L, Seow Y, Schapira AH, Rodriguez-Oroz MC, Obeso JA, Cooper JM. Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson’s disease. Cell Death Dis  2013; 4(3): e545.
 [http://dx.doi.org/10.1038/cddis.2013.73] [PMID: 23492776]

[189]
Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, et al. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol  2010; 67(12): 1464-72.
 [http://dx.doi.org/10.1001/archneurol.2010.198] [PMID: 20697033]

[190]
Xilouri M, Brekk OR, Polissidis A, Chrysanthou-Piterou M, Kloukina I, Stefanis L. Impairment of chaperone-mediated autophagy induces dopaminergic neurodegeneration in rats. Autophagy  2016; 12(11): 2230-47.
 [http://dx.doi.org/10.1080/15548627.2016.1214777] [PMID: 27541985]

[191]
Su C, Yang X, Lou J. Geniposide reduces α-synuclein by blocking microRNA-21/lysosome-associated membrane protein 2A interaction in Parkinson disease models. Brain Res  2016; 1644: 98-106.
 [http://dx.doi.org/10.1016/j.brainres.2016.05.011] [PMID: 27173998]

[192]
Li G, Yang H, Zhu D, Huang H, Liu G, Lun P. Targeted suppression of chaperone-mediated autophagy by miR-320a promotes α-synuclein aggregation. Int J Mol Sci  2014; 15(9): 15845-57.
 [http://dx.doi.org/10.3390/ijms150915845] [PMID: 25207598]

[193]
Zhang Z, Cheng Y. miR-16-1 promotes the aberrant α-synuclein accumulation in parkinson disease via targeting heat shock protein 70. ScientificWorldJournal  2014; 2014: 938348.
 [PMID: 25054189]

[194]
Piao Y, Kim HG, Oh MS, Pak YK. Overexpression of TFAM, NRF-1 and myr-AKT protects the MPP(+)-induced mitochondrial dysfunctions in neuronal cells. Biochim Biophys Acta  2012; 1820(5): 577-85.
 [http://dx.doi.org/10.1016/j.bbagen.2011.08.007] [PMID: 21856379]

[195]
Gaweda-Walerych K, Safranow K, Maruszak A, et al. Mitochondrial transcription factor A variants and the risk of Parkinson’s disease. Neurosci Lett  2010; 469(1): 24-9.
 [http://dx.doi.org/10.1016/j.neulet.2009.11.037] [PMID: 19925850]

[196]
Huang Y, Huang C, Yun W. Peripheral BDNF/TrkB protein expression is decreased in Parkinson’s disease but not in Essential tremor. J Clin Neurosci  2019; 63: 176-81.
 [http://dx.doi.org/10.1016/j.jocn.2019.01.017] [PMID: 30723034]

[197]
Cheng A, Wan R, Yang JL, et al. Involvement of PGC-1α in the formation and maintenance of neuronal dendritic spines. Nat Commun  2012; 3: 1250.
 [http://dx.doi.org/10.1038/ncomms2238] [PMID: 23212379]

[198]
Xia DY, Huang X, Bi CF, Mao LL, Peng LJ, Qian HR. PGC-1α or FNDC5 is involved in modulating the effects of Aβ1-42 oligomers on suppressing the expression of BDNF, a beneficial factor for inhibiting neuronal apoptosis, Aβ deposition and cognitive decline of APP/PS1 Tg mice. Front Aging Neurosci  2017; 9: 65.
 [http://dx.doi.org/10.3389/fnagi.2017.00065] [PMID: 28377712]

[199]
Hashemi MS, Ghaedi K, Salamian A, et al. Fndc5 knockdown significantly decreased neural differentiation rate of mouse embryonic stem cells. Neuroscience  2013; 231: 296-304.
 [http://dx.doi.org/10.1016/j.neuroscience.2012.11.041] [PMID: 23219938]

[200]
de Oliveira Bristot VJ, de Bem Alves AC, Cardoso LR, da Luz Scheffer D, Aguiar AS Jr. The role of PGC-1α/UCP2 signaling in the beneficial effects of physical exercise on the brain. Front Neurosci  2019; 13: 292.
 [http://dx.doi.org/10.3389/fnins.2019.00292] [PMID: 30983964]

[201]
Yang X, Zhang M, Wei M, Wang A, Deng Y, Cao H. MicroRNA-216a inhibits neuronal apoptosis in a cellular Parkinson’s disease model by targeting Bax. Metab Brain Dis  2020; 35(4): 627-35.
 [http://dx.doi.org/10.1007/s11011-020-00546-x] [PMID: 32140823]

[202]
Biedler JL, Helson L, Spengler BA. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res  1973; 33(11): 2643-52.
 [PMID: 4748425]

[203]
Joshi S, Guleria R, Pan J, DiPette D, Singh US. Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells. Oncogene  2006; 25(2): 240-7.
 [http://dx.doi.org/10.1038/sj.onc.1209027] [PMID: 16158052]

[204]
Ba F, Pang PK, Benishin CG. The establishment of a reliable cytotoxic system with SK-N-SH neuroblastoma cell culture. J Neurosci Methods  2003; 123(1): 11-22.
 [http://dx.doi.org/10.1016/S0165-0270(02)00324-2] [PMID: 12581845]

[205]
Zhou S, Zhang D, Guo J, Zhang J, Chen Y. Knockdown of SNHG14 alleviates MPP+-induced injury in the cell model of Parkinson’s disease by targeting the miR-214-3p/KLF4 axis. Front Neurosci  2020; 14: 930.
 [http://dx.doi.org/10.3389/fnins.2020.00930] [PMID: 33071725]

[206]
Zhou S, Zhang D, Guo J, Chen Z, Chen Y, Zhang J. Deficiency of NEAT1 prevented MPP+-induced inflammatory response, oxidative stress and apoptosis in dopaminergic SK-N-SH neuroblastoma cells via miR-1277-5p/ARHGAP26 axis. Brain Res  2021; 1750: 147156.
 [http://dx.doi.org/10.1016/j.brainres.2020.147156] [PMID: 33069733]

[207]
Saba R, Störchel PH, Aksoy-Aksel A, et al. Dopamine-regulated microRNA MiR-181a controls GluA2 surface expression in hippocampal neurons. Mol Cell Biol  2012; 32(3): 619-32.
 [http://dx.doi.org/10.1128/MCB.05896-11] [PMID: 22144581]

[208]
Moon JM, Xu L, Giffard RG. Inhibition of microRNA-181 reduces forebrain ischemia-induced neuronal loss. J Cereb Blood Flow Metab  2013; 33(12): 1976-82.
 [http://dx.doi.org/10.1038/jcbfm.2013.157] [PMID: 24002437]

[209]
Gallo KA, Johnson GL. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat Rev Mol Cell Biol  2002; 3(9): 663-72.
 [http://dx.doi.org/10.1038/nrm906] [PMID: 12209126]

[210]
Peng J, Andersen JK. The role of c-Jun N-terminal kinase (JNK) in Parkinson’s disease. IUBMB Life  2003; 55(4-5): 267-71.
 [http://dx.doi.org/10.1080/1521654031000121666] [PMID: 12880208]

[211]
Karunakaran S, Ravindranath V. Activation of p38 MAPK in the substantia nigra leads to nuclear translocation of NF-kappaB in MPTP-treated mice: implication in Parkinson’s disease. J Neurochem  2009; 109(6): 1791-9.
 [http://dx.doi.org/10.1111/j.1471-4159.2009.06112.x] [PMID: 19457134]

[212]
Liu Y, Song Y, Zhu X. MicroRNA-181a Regulates Apoptosis and Autophagy Process in Parkinson’s Disease by Inhibiting p38 Mitogen-Activated Protein Kinase (MAPK)/c-Jun N-Terminal Kinases (JNK) Signaling Pathways. Med Sci Monit  2017; 23: 1597-606.
 [http://dx.doi.org/10.12659/MSM.900218] [PMID: 28365714]

[213]
Nelson PT, Soma LA, Lavi E. Microglia in diseases of the central nervous system. Ann Med  2002; 34(7-8): 491-500.
 [http://dx.doi.org/10.1080/078538902321117698] [PMID: 12553488]

[214]
Henn A, Lund S, Hedtjärn M, Schrattenholz A, Pörzgen P, Leist M. The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. Altern Anim Exp  2009; 26(2): 83-94.
 [http://dx.doi.org/10.14573/altex.2009.2.83] [PMID: 19565166]

[215]
Wu DC, Ré DB, Nagai M, Ischiropoulos H, Przedborski S. The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc Natl Acad Sci USA  2006; 103(32): 12132-7.
 [http://dx.doi.org/10.1073/pnas.0603670103] [PMID: 16877542]

[216]
Häusler KG, Prinz M, Nolte C, et al. Interferon-gamma differentially modulates the release of cytokines and chemokines in lipopolysaccharide- and pneumococcal cell wall-stimulated mouse microglia and macrophages. Eur J Neurosci  2002; 16(11): 2113-22.
 [http://dx.doi.org/10.1046/j.1460-9568.2002.02287.x] [PMID: 12473079]

[217]
de Jong EK, de Haas AH, Brouwer N, et al. Expression of CXCL4 in microglia in vitro and in vivo and its possible signaling through CXCR3. J Neurochem  2008; 105(5): 1726-36.
 [http://dx.doi.org/10.1111/j.1471-4159.2008.05267.x] [PMID: 18248618]

[218]
Horvath RJ, Nutile-McMenemy N, Alkaitis MS, Deleo JA. Differential migration, LPS-induced cytokine, chemokine, and NO expression in immortalized BV-2 and HAPI cell lines and primary microglial cultures. J Neurochem  2008; 107(2): 557-69.
 [http://dx.doi.org/10.1111/j.1471-4159.2008.05633.x] [PMID: 18717813]

[219]
Yao L, Ye Y, Mao H, et al. MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson’s disease. J Neuroinflammation  2018; 15(1): 13.
 [http://dx.doi.org/10.1186/s12974-018-1053-4] [PMID: 29329581]

[220]
Sun Q, Wang S, Chen J, et al. MicroRNA-190 alleviates neuronal damage and inhibits neuroinflammation via Nlrp3 in MPTP-induced Parkinson’s disease mouse model. J Cell Physiol  2019; 234(12): 23379-87.
 [http://dx.doi.org/10.1002/jcp.28907] [PMID: 31232472]

[221]
Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol  1977; 36(1): 59-74.
 [http://dx.doi.org/10.1099/0022-1317-36-1-59] [PMID: 886304]

[222]
Louis N, Evelegh C, Graham FL. Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line. Virology  1997; 233(2): 423-9.
 [http://dx.doi.org/10.1006/viro.1997.8597] [PMID: 9217065]

[223]
Lin YC, Boone M, Meuris L, et al. Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. Nat Commun  2014; 5: 4767.
 [http://dx.doi.org/10.1038/ncomms5767] [PMID: 25182477]

[224]
Schwarz H, Zhang Y, Zhan C, et al. Small-scale bioreactor supports high density HEK293 cell perfusion culture for the production of recombinant Erythropoietin. J Biotechnol  2020; 309: 44-52.
 [http://dx.doi.org/10.1016/j.jbiotec.2019.12.017] [PMID: 31891733]

[225]
Shaw G, Morse S, Ararat M, Graham FL. Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J  2002; 16(8): 869-71.
 [http://dx.doi.org/10.1096/fj.01-0995fje] [PMID: 11967234]

[226]
Kaplan MP, Chin SS, Fliegner KH, Liem RK. Alpha-internexin, a novel neuronal intermediate filament protein, precedes the low molecular weight neurofilament protein (NF-L) in the developing rat brain. J Neurosci  1990; 10(8): 2735-48.
 [http://dx.doi.org/10.1523/JNEUROSCI.10-08-02735.1990] [PMID: 2201753]

[227]
Shaw G, Weber K. Differential expression of neurofilament triplet proteins in brain development. Nature  1982; 298(5871): 277-9.
 [http://dx.doi.org/10.1038/298277a0] [PMID: 7045694]

[228]
Dautzenberg FM, Higelin J, Teichert U. Functional characterization of corticotropin-releasing factor type 1 receptor endogenously expressed in human embryonic kidney 293 cells. Eur J Pharmacol  2000; 390(1-2): 51-9.
 [http://dx.doi.org/10.1016/S0014-2999(99)00915-2] [PMID: 10708706]

[229]
Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature  1997; 390(6655): 88-91.
 [http://dx.doi.org/10.1038/36362] [PMID: 9363896]

[230]
van Koppen C, Meyer zu Heringdorf M, Laser KT, et al. Activation of a high affinity Gi protein-coupled plasma membrane receptor by sphingosine-1-phosphate. J Biol Chem  1996; 271(4): 2082-7.
 [http://dx.doi.org/10.1074/jbc.271.4.2082] [PMID: 8567663]

[231]
Schachter JB, Sromek SM, Nicholas RA, Harden TK. HEK293 human embryonic kidney cells endogenously express the P2Y1 and P2Y2 receptors. Neuropharmacology  1997; 36(9): 1181-7.
 [http://dx.doi.org/10.1016/S0028-3908(97)00138-X] [PMID: 9364473]

[232]
Lin K, Sadée W, Quillan JM. Rapid measurements of intracellular calcium using a fluorescence plate reader. Biotechniques  1999; 26(2): 318-322, 324-326.
 [http://dx.doi.org/10.2144/99262rr02] [PMID: 10023544]

[233]
Doxakis E. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J Biol Chem  2010; 285(17): 12726-34.
 [http://dx.doi.org/10.1074/jbc.M109.086827] [PMID: 20106983]

[234]
Fragkouli A, Doxakis E. miR-7 and miR-153 protect neurons against MPP(+)-induced cell death via upregulation of mTOR pathway. Front Cell Neurosci  2014; 8: 182.
 [http://dx.doi.org/10.3389/fncel.2014.00182] [PMID: 25071443]

[235]
Lim W, Song G. Identification of novel regulatory genes in development of the avian reproductive tracts. PLoS One  2014; 9(4): e96175.
 [http://dx.doi.org/10.1371/journal.pone.0096175] [PMID: 24763497]

[236]
Bargmann CI. Neurobiology of the Caenorhabditis elegans genome. Science  1998; 282(5396): 2028-33.
 [http://dx.doi.org/10.1126/science.282.5396.2028] [PMID: 9851919]

[237]
Sulston J, Dew M, Brenner S. Dopaminergic neurons in the nematode Caenorhabditis elegans. J Comp Neurol  1975; 163(2): 215-26.
 [http://dx.doi.org/10.1002/cne.901630207] [PMID: 240872]

[238]
Kim W, Underwood RS, Greenwald I, Shaye DD. OrthoList 2: A new comparative genomic analysis of human and Caenorhabditis elegans genes. Genetics  2018; 210(2): 445-61.
 [http://dx.doi.org/10.1534/genetics.118.301307] [PMID: 30120140]

[239]
Grosshans H, Johnson T, Reinert KL, Gerstein M, Slack FJ. The temporal patterning microRNA let-7 regulates several transcription factors at the larval to adult transition in C. elegans. Dev Cell  2005; 8(3): 321-30.
 [http://dx.doi.org/10.1016/j.devcel.2004.12.019] [PMID: 15737928]

[240]
Tehrani N, Del Rosario J, Dominguez M, Kalb R, Mano I. The insulin/IGF signaling regulators cytohesin/GRP-1 and PIP5K/PPK-1 modulate susceptibility to excitotoxicity in C. elegans. PLoS One  2014; 9(11): e113060.
 [http://dx.doi.org/10.1371/journal.pone.0113060] [PMID: 25422944]

[241]
Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol  2000; 1(2): 120-9.
 [http://dx.doi.org/10.1038/35040009] [PMID: 11253364]

[242]
Aballay A, Ausubel FM. Programmed cell death mediated by ced-3 and ced-4 protects Caenorhabditis elegans from Salmonella typhimurium-mediated killing. Proc Natl Acad Sci USA  2001; 98(5): 2735-9.
 [http://dx.doi.org/10.1073/pnas.041613098] [PMID: 11226309]

[243]
Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene  2008; 27(48): 6245-51.
 [http://dx.doi.org/10.1038/onc.2008.301] [PMID: 18931691]

[244]
Reiter LT, Potocki L, Chien S, Gribskov M, Bier E. A systematic analysis of human disease-associated gene sequences in Drosophila melanogaster. Genome Res  2001; 11(6): 1114-25.
 [http://dx.doi.org/10.1101/gr.169101] [PMID: 11381037]

[245]
Lim KL, Ng CH. Genetic models of Parkinson disease. Biochim Biophys Acta  2009; 1792(7): 604-15.
 [http://dx.doi.org/10.1016/j.bbadis.2008.10.005] [PMID: 19000757]

[246]
Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson’s disease. Neuron  2010; 66(5): 646-61.
 [http://dx.doi.org/10.1016/j.neuron.2010.04.034] [PMID: 20547124]

[247]
Lu B, Vogel H. Drosophila models of neurodegenerative diseases. Annu Rev Pathol  2009; 4: 315-42.
 [http://dx.doi.org/10.1146/annurev.pathol.3.121806.151529] [PMID: 18842101]

[248]
Ambegaokar SS, Roy B, Jackson GR. Neurodegenerative models in Drosophila: polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis. Neurobiol Dis  2010; 40(1): 29-39.
 [http://dx.doi.org/10.1016/j.nbd.2010.05.026] [PMID: 20561920]

[249]
Hirth F. Drosophila melanogaster in the study of human neurodegeneration. CNS Neurol Disord Drug Targets  2010; 9(4): 504-23.
 [http://dx.doi.org/10.2174/187152710791556104] [PMID: 20522007]

[250]
Botella JA, Bayersdorfer F, Gmeiner F, Schneuwly S. Modelling Parkinson’s disease in Drosophila. Neuromolecular Med  2009; 11(4): 268-80.
 [http://dx.doi.org/10.1007/s12017-009-8098-6] [PMID: 19855946]

[251]
Park J, Kim Y, Chung J. Mitochondrial dysfunction and Parkinson’s disease genes: insights from Drosophila. Dis Model Mech  2009; 2(7-8): 336-40.
 [http://dx.doi.org/10.1242/dmm.003178] [PMID: 19553694]

[252]
Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development  1993; 118(2): 401-15.
 [http://dx.doi.org/10.1242/dev.118.2.401] [PMID: 8223268]

[253]
Muñoz-Soriano V, Paricio N. Drosophila models of Parkinson’s disease: discovering relevant pathways and novel therapeutic strategies. Parkinsons Dis  2011; 2011: 520640.
 [http://dx.doi.org/10.4061/2011/520640] [PMID: 21512585]

[254]
Kong Y, Liang X, Liu L, et al. High throughput sequencing identifies microRNAs mediating α-synuclein toxicity by targeting neuroactive-ligand receptor interaction pathway in early stage of Drosophila Parkinson’s disease model. PLoS One  2015; 10(9): e0137432.
 [http://dx.doi.org/10.1371/journal.pone.0137432] [PMID: 26361355]

[255]
Strazisar M, Cammaerts S, van der Ven K, et al. MIR137 variants identified in psychiatric patients affect synaptogenesis and neuronal transmission gene sets. Mol Psychiatry  2015; 20(4): 472-81.
 [http://dx.doi.org/10.1038/mp.2014.53] [PMID: 24888363]

[256]
Jiang Y, Liu J, Chen L, et al. Serum secreted miR-137-containing exosomes affects oxidative stress of neurons by regulating OXR1 in Parkinson’s disease. Brain Res  2019; 1722: 146331.
 [http://dx.doi.org/10.1016/j.brainres.2019.146331] [PMID: 31301273]

[257]
Verma P, Augustine GJ, Ammar MR, Tashiro A, Cohen SM. A neuroprotective role for microRNA miR-1000 mediated by limiting glutamate excitotoxicity. Nat Neurosci  2015; 18(3): 379-85.
 [http://dx.doi.org/10.1038/nn.3935] [PMID: 25643297]

[258]
Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron  2003; 39(6): 889-909.
 [http://dx.doi.org/10.1016/S0896-6273(03)00568-3] [PMID: 12971891]

[259]
Schober A. Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res  2004; 318(1): 215-24.
 [http://dx.doi.org/10.1007/s00441-004-0938-y] [PMID: 15503155]

[260]
Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson’s disease. BioEssays  2002; 24(4): 308-18.
 [http://dx.doi.org/10.1002/bies.10067] [PMID: 11948617]

[261]
Zhou Y, Lu M, Du RH, et al. MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson’s disease. Mol Neurodegener  2016; 11: 28.
 [http://dx.doi.org/10.1186/s13024-016-0094-3] [PMID: 27084336]

[262]
Levy OA, Malagelada C, Greene LA. Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps. Apoptosis  2009; 14(4): 478-500.
 [http://dx.doi.org/10.1007/s10495-008-0309-3] [PMID: 19165601]

[263]
Kaur B, Prakash A. Ceftriaxone attenuates glutamate-mediated neuro-inflammation and restores BDNF in MPTP model of Parkinson’s disease in rats. Pathophysiology  2017; 24(2): 71-9.
 [http://dx.doi.org/10.1016/j.pathophys.2017.02.001] [PMID: 28245954]

[264]
Nuber S, Tadros D, Fields J, et al. Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD. Acta Neuropathol  2014; 127(4): 477-94.
 [http://dx.doi.org/10.1007/s00401-014-1255-5] [PMID: 24509835]

[265]
Li D, Yang H, Ma J, Luo S, Chen S, Gu Q. MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson’s disease by targeting Nlrp3. Hum Cell  2018; 31(2): 106-15.
 [http://dx.doi.org/10.1007/s13577-017-0187-5] [PMID: 29274035]

[266]
Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci  2001; 21(24): 9549-60.
 [http://dx.doi.org/10.1523/JNEUROSCI.21-24-09549.2001] [PMID: 11739566]

[267]
Jiang H, Wu YC, Nakamura M, et al. Parkinson’s disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2 and Sin-1-induced cell death. Neurobiol Aging  2007; 28(11): 1709-17.
 [http://dx.doi.org/10.1016/j.neurobiolaging.2006.07.017] [PMID: 16978743]

[268]
Junn E, Mouradian MM. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett  2002; 320(3): 146-50.
 [http://dx.doi.org/10.1016/S0304-3940(02)00016-2] [PMID: 11852183]

[269]
Kim J, Inoue K, Ishii J, et al. A MicroRNA feedback circuit in midbrain dopamine neurons. Science  2007; 317(5842): 1220-4.
 [http://dx.doi.org/10.1126/science.1140481] [PMID: 17761882]

[270]
Hwang DY, Ardayfio P, Kang UJ, Semina EV, Kim KS. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res Mol Brain Res  2003; 114(2): 123-31.
 [http://dx.doi.org/10.1016/S0169-328X(03)00162-1] [PMID: 12829322]

[271]
Martinat C, Bacci JJ, Leete T, et al. Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype. Proc Natl Acad Sci USA  2006; 103(8): 2874-9.
 [http://dx.doi.org/10.1073/pnas.0511153103] [PMID: 16477036]

[272]
Nunes I, Tovmasian LT, Silva RM, Burke RE, Goff SP. Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc Natl Acad Sci USA  2003; 100(7): 4245-50.
 [http://dx.doi.org/10.1073/pnas.0230529100] [PMID: 12655058]

[273]
Ma L, Wei L, Wu F, Hu Z, Liu Z, Yuan W. Advances with microRNAs in Parkinson’s disease research. Drug Des Devel Ther  2013; 7: 1103-13.
 [PMID: 24109179]

[274]
Sarkar S, Chigurupati S, Raymick J, et al. Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson’s disease mouse model. Neurotoxicology  2014; 44: 250-62.
 [http://dx.doi.org/10.1016/j.neuro.2014.07.006] [PMID: 25064079]

[275]
Rosas-Hernandez H, Chigurupati S, Raymick J, et al. Identification of altered microRNAs in serum of a mouse model of Parkinson’s disease. Neurosci Lett  2018; 687: 1-9.
 [http://dx.doi.org/10.1016/j.neulet.2018.07.022] [PMID: 30025832]

[276]
Wang H, Ye Y, Zhu Z, et al. MiR-124 regulates apoptosis and autophagy process in MPTP model of Parkinson’s disease by targeting to Bim. Brain Pathol  2016; 26(2): 167-76.
 [http://dx.doi.org/10.1111/bpa.12267] [PMID: 25976060]

[277]
Mishima T, Mizuguchi Y, Kawahigashi Y, Takizawa T, Takizawa T. RT-PCR-based analysis of microRNA (miR-1 and -124) expression in mouse CNS. Brain Res  2007; 1131(1): 37-43.
 [http://dx.doi.org/10.1016/j.brainres.2006.11.035] [PMID: 17182009]

[278]
Saraiva C, Paiva J, Santos T, Ferreira L, Bernardino L. MicroRNA-124 loaded nanoparticles enhance brain repair in Parkinson’s disease. J Control Release  2016; 235: 291-305.
 [http://dx.doi.org/10.1016/j.jconrel.2016.06.005] [PMID: 27269730]

[279]
Sun Y, Li Q, Gui H, et al. MicroRNA-124 mediates the cholinergic anti-inflammatory action through inhibiting the production of pro-inflammatory cytokines. Cell Res  2013; 23(11): 1270-83.
 [http://dx.doi.org/10.1038/cr.2013.116] [PMID: 23979021]

[280]
Chen L, Gan L, Zhou HY, Liang JH. Protective effects of miR-19b in Parkinson’s disease by inhibiting the activation of iNOS through negative regulation of p38 signaling pathways. Int J Clin Exp  2019; 12(5): 4735-44.

[281]
Xiong R, Wang Z, Zhao Z, et al. MicroRNA-494 reduces DJ-1 expression and exacerbates neurodegeneration. Neurobiol Aging  2014; 35(3): 705-14.
 [http://dx.doi.org/10.1016/j.neurobiolaging.2013.09.027] [PMID: 24269020]

[282]
Montoya CP, Campbell-Hope LJ, Pemberton KD, Dunnett SB. The “staircase test”: a measure of independent forelimb reaching and grasping abilities in rats. J Neurosci Methods  1991; 36(2-3): 219-28.
 [http://dx.doi.org/10.1016/0165-0270(91)90048-5] [PMID: 2062117]

[283]
Olsson M, Nikkhah G, Bentlage C, Björklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci  1995; 15(5 Pt 2): 3863-75.
 [http://dx.doi.org/10.1523/JNEUROSCI.15-05-03863.1995] [PMID: 7751951]

[284]
Lindner MD, Plone MA, Francis JM, Emerich DF. Validation of a rodent model of Parkinson’s Disease: evidence of a therapeutic window for oral Sinemet. Brain Res Bull  1996; 39(6): 367-72.
 [http://dx.doi.org/10.1016/0361-9230(96)00027-5] [PMID: 9138746]

[285]
Rozas G, Guerra MJ, Labandeira-García JL. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc  1997; 2(1): 75-84.
 [http://dx.doi.org/10.1016/S1385-299X(97)00034-2] [PMID: 9438075]

[286]
Cenci MA, Lee CS, Björklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci  1998; 10(8): 2694-706.
 [http://dx.doi.org/10.1046/j.1460-9568.1998.00285.x] [PMID: 9767399]

[287]
Lee CS, Cenci MA, Schulzer M, Björklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson’s disease. Brain  2000; 123(Pt 7): 1365-79.
 [http://dx.doi.org/10.1093/brain/123.7.1365] [PMID: 10869049]

[288]
Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology  2000; 39(5): 777-87.
 [http://dx.doi.org/10.1016/S0028-3908(00)00005-8] [PMID: 10699444]

[289]
Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur J Neurosci  2002; 15(1): 120-32.
 [http://dx.doi.org/10.1046/j.0953-816x.2001.01843.x] [PMID: 11860512]

[290]
Wu DM, Wang S, Wen X, et al. Inhibition of microRNA-200a upregulates the expression of striatal dopamine receptor D2 to repress apoptosis of striatum via the cAMP/PKA signaling pathway in rats with Parkinson’s disease. Cell Physiol Biochem  2018; 51(4): 1600-15.
 [http://dx.doi.org/10.1159/000495649] [PMID: 30497067]

[291]
Ma X, Zhang H, Yin H, et al. Up-regulated microRNA-218-5p ameliorates the damage of dopaminergic neurons in rats with Parkinson’s disease via suppression of LASP1. Brain Res Bull  2021; 166: 92-101.
 [http://dx.doi.org/10.1016/j.brainresbull.2020.10.019] [PMID: 33144090]

[292]
Lungu G, Stoica G, Ambrus A. MicroRNA profiling and the role of microRNA-132 in neurodegeneration using a rat model. Neurosci Lett  2013; 553: 153-8.
 [http://dx.doi.org/10.1016/j.neulet.2013.08.001] [PMID: 23973300]

[293]
Sardiello M, Palmieri M, di Ronza A, et al. A gene network regulating lysosomal biogenesis and function. Science  2009; 325(5939): 473-7.
 [http://dx.doi.org/10.1126/science.1174447] [PMID: 19556463]

[294]
Settembre C, Di Malta C, Polito VA, et al. TFEB links autophagy to lysosomal biogenesis. Science  2011; 332(6036): 1429-33.
 [http://dx.doi.org/10.1126/science.1204592] [PMID: 21617040]

[295]
Peña-Llopis S, Vega-Rubin-de-Celis S, Schwartz JC, et al. Regulation of TFEB and V-ATPases by mTORC1. EMBO J  2011; 30(16): 3242-58.
 [http://dx.doi.org/10.1038/emboj.2011.257] [PMID: 21804531]

[296]
Settembre C, Zoncu R, Medina DL, et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J  2012; 31(5): 1095-108.
 [http://dx.doi.org/10.1038/emboj.2012.32] [PMID: 22343943]

[297]
Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Björklund A. TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc Natl Acad Sci USA  2013; 110(19): E1817-26.
 [http://dx.doi.org/10.1073/pnas.1305623110] [PMID: 23610405]

[298]
Bortolozzi A, Manashirov S, Chen A, Artigas F. Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson’s disease. Pharmacol Ther  2021; 227: 107873.
 [http://dx.doi.org/10.1016/j.pharmthera.2021.107873] [PMID: 33915178]

[299]
Titze-de-Almeida R, Titze-de-Almeida SS. miR-7 replacement therapy in Parkinson’s disease. Curr Gene Ther  2018; 18(3): 143-53.
 [http://dx.doi.org/10.2174/1566523218666180430121323] [PMID: 29714132]

[300]
Kumar S, Mapa K, Maiti S. Understanding the effect of locked nucleic acid and 2′-O-methyl modification on the hybridization thermodynamics of a miRNA-mRNA pair in the presence and absence of AfPiwi protein. Biochemistry  2014; 53(10): 1607-15.
 [http://dx.doi.org/10.1021/bi401677d] [PMID: 24564489]

[301]
Leggio L, Vivarelli S, L’Episcopo F, et al. MicroRNAs in Parkinson’s disease: From pathogenesis to novel diagnostic and therapeutic approaches. Int J Mol Sci  2017; 18(12): 2698.
 [http://dx.doi.org/10.3390/ijms18122698] [PMID: 29236052]

[302]
Pickard MR, Chari DM. Robust uptake of magnetic nanoparticles (MNPs) by central nervous system (CNS) microglia: implications for particle uptake in mixed neural cell populations. Int J Mol Sci  2010; 11(3): 967-81.
 [http://dx.doi.org/10.3390/ijms11030967] [PMID: 20479995]

[303]
Titze-de-Almeida SS, Soto-Sánchez C, Fernandez E, Koprich JB, Brotchie JM, Titze-de-Almeida R. The promise and challenges of developing miRNA-based therapeutics for Parkinson’s disease. Cells  2020; 9(4): 841.
 [http://dx.doi.org/10.3390/cells9040841] [PMID: 32244357]

[304]
Keeler AM, ElMallah MK, Flotte TR. Gene therapy 2017: Progress and future directions. Clin Transl Sci  2017; 10(4): 242-8.
 [http://dx.doi.org/10.1111/cts.12466] [PMID: 28383804]

[305]
Myoung SS, Kasinski AL. Strategies for safe and targeted delivery of microRNA therapeutics. MicroRNAs in Diseases and Disorders  2019; 386-415.

[306]
Yang N. An overview of viral and nonviral delivery systems for microRNA. Int J Pharm Investig  2015; 5(4): 179-81.
 [http://dx.doi.org/10.4103/2230-973X.167646] [PMID: 26682187]

[307]
Paul S, Bravo Vázquez LA, Pérez Uribe S, Roxana Reyes-Pérez P, Sharma A. Current status of microRNA-based therapeutic approaches in neurodegenerative disorders. Cells  2020; 9(7): 1698.
 [http://dx.doi.org/10.3390/cells9071698] [PMID: 32679881]

[308]
Wen MM. Getting miRNA therapeutics into the target cells for neurodegenerative diseases: A mini-review. Front Mol Neurosci  2016; 9: 129.
 [http://dx.doi.org/10.3389/fnmol.2016.00129] [PMID: 27920668]

[309]
Vieira DB, Gamarra LF. Getting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrier. Int J Nanomedicine  2016; 11: 5381-414.
 [http://dx.doi.org/10.2147/IJN.S117210] [PMID: 27799765]

[310]
Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B  2016; 6(4): 287-96.
 [http://dx.doi.org/10.1016/j.apsb.2016.02.001] [PMID: 27471669]

[311]
Yang J, Luo S, Zhang J, et al. Exosome-mediated delivery of antisense oligonucleotides targeting α-synuclein ameliorates the pathology in a mouse model of Parkinson’s disease. Neurobiol Dis  2021; 148: 105218.
 [http://dx.doi.org/10.1016/j.nbd.2020.105218] [PMID: 33296726]

[312]
Chen Y, Gao DY, Huang L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev  2015; 81: 128-41.
 [http://dx.doi.org/10.1016/j.addr.2014.05.009] [PMID: 24859533]

[313]
Cosco D, Cilurzo F, Maiuolo J, et al. Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma. Sci Rep  2015; 5: 17579.
 [http://dx.doi.org/10.1038/srep17579] [PMID: 26620594]

[314]
Saraiva C, Talhada D, Rai A, et al. MicroRNA-124-loaded nanoparticles increase survival and neuronal differentiation of neural stem cells in vitro but do not contribute to stroke outcome in vivo. PLoS One  2018; 13(3): e0193609.
 [http://dx.doi.org/10.1371/journal.pone.0193609] [PMID: 29494665]

[315]
Lee HJ, Namgung R, Kim WJ, Kim JI, Park IK. Targeted delivery of microRNA-145 to metastatic breast cancer by peptide conjugated branched PEI gene carrier. Macromol Res  2013; 21(11): 1201-9.
 [http://dx.doi.org/10.1007/s13233-013-1161-z]

[316]
Ibrahim AF, Weirauch U, Thomas M, Grünweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res  2011; 71(15): 5214-24.
 [http://dx.doi.org/10.1158/0008-5472.CAN-10-4645] [PMID: 21690566]

[317]
Liu Q, Li RT, Qian HQ, et al. Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. Biomaterials  2013; 34(29): 7191-203.
 [http://dx.doi.org/10.1016/j.biomaterials.2013.06.004] [PMID: 23806972]

[318]
Chiou GY, Cherng JY, Hsu HS, et al. Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J Control Release  2012; 159(2): 240-50.
 [http://dx.doi.org/10.1016/j.jconrel.2012.01.014] [PMID: 22285547]

[319]
Yang YP, Chien Y, Chiou GY, et al. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials  2012; 33(5): 1462-76.
 [http://dx.doi.org/10.1016/j.biomaterials.2011.10.071] [PMID: 22098779]

[320]
Höbel S, Aigner A. Polyethylenimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip Rev Nanomed Nanobiotechnol  2013; 5(5): 484-501.
 [http://dx.doi.org/10.1002/wnan.1228] [PMID: 23720168]

[321]
Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release  2012; 161(2): 505-22.
 [http://dx.doi.org/10.1016/j.jconrel.2012.01.043] [PMID: 22353619]

[322]
Wong SY, Pelet JM, Putnam D. Polymer systems for gene delivery-past, present, and future. Prog Polym Sci  2007; 32(8-9): 799-837.
 [http://dx.doi.org/10.1016/j.progpolymsci.2007.05.007]

[323]
Serrano MC, Pagani R, Vallet-Regí M, et al. In vitro biocompatibility assessment of poly(epsilon-caprolactone) films using L929 mouse fibroblasts. Biomaterials  2004; 25(25): 5603-11.
 [http://dx.doi.org/10.1016/j.biomaterials.2004.01.037] [PMID: 15159076]

[324]
Sekhon BS, Kamboj SR. Inorganic nanomedicine-part 1. Nanomedicine  2010; 6(4): 516-22.
 [http://dx.doi.org/10.1016/j.nano.2010.04.004] [PMID: 20417313]

[325]
Sekhon BS, Kamboj SR. Inorganic nanomedicine-part 2. Nanomedicine  2010; 6(5): 612-8.
 [http://dx.doi.org/10.1016/j.nano.2010.04.003] [PMID: 20417314]

[326]
Lee SWL, Paoletti C, Campisi M, et al. MicroRNA delivery through nanoparticles. J Control Release  2019; 313: 80-95.
 [http://dx.doi.org/10.1016/j.jconrel.2019.10.007] [PMID: 31622695]

[327]
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell  2006; 126(4): 663-76.
 [http://dx.doi.org/10.1016/j.cell.2006.07.024] [PMID: 16904174]

[328]
Dey SK, Jaffrey SR. RIBOTACs: Small molecules target RNA for degradation. Cell Chem Biol  2019; 26(8): 1047-9.
 [http://dx.doi.org/10.1016/j.chembiol.2019.07.015] [PMID: 31419417]

[329]
Gabr MT, Brogi S. MicroRNA-based multitarget approach for Alzheimer’s disease: Discovery of the first-in-class dual inhibitor of acetylcholinesterase and microRNA-15b biogenesis. J Med Chem  2020; 63(17): 9695-704.
 [http://dx.doi.org/10.1021/acs.jmedchem.0c00756] [PMID: 32787143]

[330]
Abdelrahman SA, Gabr MT. Emerging small-molecule therapeutic approaches for Alzheimer’s disease and Parkinson’s disease based on targeting microRNAs. Neural Regen Res  2022; 17(2): 336-7.
 [http://dx.doi.org/10.4103/1673-5374.317977] [PMID: 34269206]

[331]
Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology  2007; 68(5): 384-6.
 [http://dx.doi.org/10.1212/01.wnl.0000247740.47667.03] [PMID: 17082464]
Rights & Permissions Print Cite
Article Metrics
37
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1871527321666220111152756	Print ISSN 1871-5273
Publisher Name Bentham Science Publisher	Online ISSN 1996-3181
CNS & Neurological Disorders - Drug Targets

A Comprehensive Study of miRNAs in Parkinson’s Disease: Diagnostics and Therapeutic Approaches

Abstract

Heart and Brain Axis Targets in CNS Neurological Disorders

Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia

Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities

Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches

CNS & Neurological Disorders - Drug Targets

A Comprehensive Study of miRNAs in Parkinson’s Disease: Diagnostics and Therapeutic Approaches

Abstract

Call for Papers in Thematic Issues

Heart and Brain Axis Targets in CNS Neurological Disorders

Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia

Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities

Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches

Related Journals

Related Books

Related Articles
